Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) EVP Neena Patil sold 1,200 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Jazz Pharmaceuticals Trading Down 2.4%
NASDAQ:JAZZ traded down $5.61 on Friday, hitting $230.56. The stock had a trading volume of 635,707 shares, compared to its average volume of 993,192. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The stock has a market cap of $14.48 billion, a price-to-earnings ratio of -11,522.24, a PEG ratio of 0.21 and a beta of 0.32. The company has a fifty day moving average price of $216.77 and a two-hundred day moving average price of $188.55. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion for the quarter. Equities research analysts expect that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Jazz Pharmaceuticals
Institutional Investors Weigh In On Jazz Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 132.6% during the first quarter. NewEdge Advisors LLC now owns 1,975 shares of the specialty pharmaceutical company’s stock worth $373,000 after buying an additional 1,126 shares in the last quarter. Glenmede Trust Co. NA grew its stake in Jazz Pharmaceuticals by 1.9% during the first quarter. Glenmede Trust Co. NA now owns 7,819 shares of the specialty pharmaceutical company’s stock worth $1,478,000 after buying an additional 146 shares during the period. Bank of America Corp DE grew its stake in Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after buying an additional 99,656 shares during the period. Tri Locum Partners LP acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth $29,995,000. Finally, Amundi lifted its position in shares of Jazz Pharmaceuticals by 2,445.3% during the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock worth $10,519,000 after purchasing an additional 53,454 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
